好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Developing NF1-specific Brain Growth Charts from Clinical Brain MRIs: A Framework for Classifying Image Pathology and Suitability for Quantitative Image Processing
Neuro-oncology
S13 - Neuro-oncology: Advances in Diagnosis and Treatments (2:24 PM-2:36 PM)
008

To classify pathology in clinical brain MRIs of Neurofibromatosis Type 1 (NF1), for the purpose of creating NF1-specific brain growth charts. 

NF1 is an autosomal dominant disorder occurring in approximately 1 in 3000 births. The disorder is associated with nervous system tumors, macrocephaly, and increased rates of neurodevelopmental disorders including autism and ADHD. Thus, it is critical to understand NF1 brain growth trajectories and co-occurring pathology. However, prior work on NF1 brain growth is limited, particularly in early childhood. Clinically-acquired brain MRIs provide an untapped data resource to address these knowledge gaps.

Prior to generating brain growth charts from clinical MRIs, it is first necessary to annotate brain pathology that may affect quantitative image processing. We applied the following NF1-specific grading system to MRI radiology reports of NF1 patients at the Children’s Hospital of Philadelphia: Grade_0 (severe pathology that likely precludes automated image processing, e.g., extensive tumor); Grade_1 (intermediate pathology that likely does not interfere with image processing, e.g. small optic pathway glioma, <1cm largest dimension); Grade_2 (minimal/no pathology). Grade_1 sessions underwent manual annotation for specific pathologies. Anatomical MRIs from Grade_1 and Grade_2 sessions were processed with recon-all-clinical (FreeSurfer v7.4.1).

7,580 MRI sessions from 754 NF1 patients age 0-21y were graded (Grade_0, n=2646; Grade_1, n=3444; Grade_2, n=1490. Ongoing Grade_1 annotation completed on 90% of scans revealed common NF1 pathologies (optic pathway glioma, n=1765; possible but unconfirmed non-optic pathway intracranial gliomas, n=870; prominent ventricles, ventriculomegaly, n=295; sphenoid dysplasia, n=272). Median age-at-scan differed significantly across grades, likely reflecting longitudinal progression of pathology (Grade_0 median=10.9y; Grade_1 median=7.4y; Grade_2 median=4.7y; χ²=948.1, p<2.2x10-16). MRIs from Grade_1 and Grade_2 sessions were successfully processed allowing for quantification of global and regional brain volumes.

This work establishes a foundation for developing NF1-specific growth charts from clinical brain MRIs, advancing our understanding of NF1 brain development and brain-behavior relationships. 

Authors/Disclosures
Habib E. Akouri
PRESENTER
Mr. Akouri has nothing to disclose.
Ayan S. Mandal, PhD Dr. Mandal has nothing to disclose.
Milo Writer Mr. Writer has nothing to disclose.
Matthew Buczek Mr. Buczek has nothing to disclose.
Susan Sotardi, MD Dr. Sotardi has nothing to disclose.
Arastoo Vossough, MD (University of Pennsylvania - Children'S Hospital of Philadelphia) Dr. Vossough has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Syneos Health. Dr. Vossough has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for DeepSight. Dr. Vossough has received publishing royalties from a publication relating to health care.
Viveknarayanan Padmanabhan Mr. Padmanabhan has nothing to disclose.
Remo M. Williams Mr. Williams has nothing to disclose.
Gareth Ball, PhD Dr. Ball has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley Publishing. The institution of Dr. Ball has received research support from NHMRC.
Jonathan Payne, DPsych Prof. Payne has nothing to disclose.
Kathryn North, MD, MBBS, FRACP Dr. North has nothing to disclose.
Nils Muhlert, PhD Dr. Muhlert has nothing to disclose.
Shruti Garg, MD, PhD The institution of Dr. Garg has received research support from US Department of Defence.
Jakob Seidlitz, PhD Dr. Seidlitz has stock in Centile Bioscience.
Michael Fisher, MD Dr. Fisher has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Fisher has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Day One. Dr. Fisher has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks. The institution of Dr. Fisher has received research support from AstraZeneca/Alexion. The institution of Dr. Fisher has received research support from Array BioPharma.
Aaron F. Alexander-Bloch, MD, PhD Mr. Alexander-Bloch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Bioscience. Mr. Alexander-Bloch has stock in Centile Bioscience. The institution of Mr. Alexander-Bloch has received research support from NIH. The institution of Mr. Alexander-Bloch has received research support from DOD. Mr. Alexander-Bloch has received intellectual property interests from a discovery or technology relating to health care. Mr. Alexander-Bloch has received personal compensation in the range of $0-$499 for serving as a Grant reviewer with NIH.